In a 78-year-old woman with end-stage renal disease on thrice‑weekly dialysis who has uncontrolled hypertension with systolic pressures in the 190–200 mm Hg range despite amlodipine 10 mg daily, clonidine 0.2 mg weekly patch, and losartan 100 mg daily, what medication adjustments can be made to achieve better blood pressure control?

Medication Adjustments for Uncontrolled Hypertension in Dialysis

Discontinue clonidine immediately and add a thiazide-like diuretic (if residual kidney function exists) or a beta-blocker as your next agent, while ensuring optimal volume control through dialysis. 1, 2

Critical Issue: Clonidine Should Be Avoided

The most important adjustment is stopping the clonidine patch. Multiple guidelines explicitly recommend against clonidine in high-risk cardiovascular patients. The 2007 AHA statement notes that clonidine "should probably be avoided" because moxonidine (same drug class) was associated with increased mortality in heart failure patients 1. The 2020 ISH guidelines list clonidine only as a last-resort agent after spironolactone, amiloride, doxazosin, eplerenone, and beta-blockers have failed 2. In dialysis patients with end-stage renal disease and likely significant cardiovascular disease, clonidine carries unacceptable risk.

Optimal Medication Strategy

Step 1: Maximize Current Regimen

• Losartan 100 mg is already at maximum dose 3
• Amlodipine 10 mg is already at maximum dose
• Both are appropriate choices for dialysis patients and are non-dialyzable 4, 5, 6

Step 2: Add a Beta-Blocker (First Choice)

Add carvedilol, metoprolol succinate, or bisoprolol as these have proven mortality benefits 1, 7, 6. Recent evidence suggests beta-blockers may be more effective than RAS blockers in dialysis patients for reducing blood pressure and preventing cardiovascular complications 7. Beta-blockers also reduce left ventricular hypertrophy and ventricular arrhythmias, which are critical in this population 8.

Practical consideration: If using atenolol or other dialyzable beta-blockers, dose after each dialysis session (Monday, Wednesday, Friday) to maintain therapeutic levels 6, 8.

Step 3: Consider Adding a Diuretic (If Residual Function)

If the patient has any residual urine output, add a thiazide-like diuretic (chlorthalidone or indapamide) 9, 2. Loop diuretics may help preserve residual kidney function and reduce interdialytic weight gain 4, 5. However, diuretics have minimal antihypertensive effect in anuric dialysis patients 4.

Step 4: Resistant Hypertension Protocol

If blood pressure remains uncontrolled after the above adjustments, add spironolactone 25 mg daily (monitor potassium closely) 2, 4. Mineralocorticoid receptor antagonists are effective for refractory hypertension in dialysis patients, though hyperkalemia risk requires vigilant monitoring 10, 4.

Volume Management is Paramount

Before intensifying medications further, reassess dry weight and sodium control:

• Probe dry weight downward by 0.5-1.0 kg increments 7, 6, 11
• Prescribe individualized dialysate sodium (typically 135-138 mEq/L) to prevent intradialytic sodium loading 7, 6
• Enforce strict dietary sodium restriction (<2 g/day) 7, 6, 11
• Consider longer or more frequent dialysis sessions if volume overload persists 11

Volume overload is the primary driver of hypertension in dialysis patients, and medication adjustments without addressing volume status will likely fail 7, 6, 11.

Monitoring Strategy

• Check blood pressure at home between dialysis sessions, as pre-dialysis readings correlate poorly with cardiovascular outcomes 6, 12
• Target blood pressure <140/90 mm Hg (individualized for frailty in elderly patients) 2
• Monitor potassium within 2-4 weeks after adding spironolactone or adjusting RAS blockade 10
• Assess for intradialytic hypotension if dry weight is aggressively reduced 4

Common Pitfalls to Avoid

1. Do not combine ACE inhibitor with ARB - this patient is already on losartan (ARB), so adding an ACE inhibitor is contraindicated 9, 13, 10
2. Do not rely solely on pre-dialysis blood pressure readings - these correlate poorly with outcomes 6, 12
3. Do not overlook medication adherence - consider supervised dosing after dialysis for key agents 6, 8
4. Do not ignore volume status - medication escalation without volume control is futile 7, 6, 11

Dialyzability Considerations

• Losartan (ARB): Non-dialyzable, no supplemental dosing needed 14, 5
• Amlodipine (CCB): Non-dialyzable, maintains stable levels 4, 5, 6
• Clonidine: Minimally removed by dialysis, but should be discontinued regardless 14
• Beta-blockers: Variable (atenolol is dialyzable; carvedilol is not) - choose based on desired pharmacokinetics 6, 8